Angiogenesis and the progress of vascular and tumor biology: A tribute to Judah Folkman

Maria Benedetta Donati; Joanna Gozdzikiewicz

doi:10.1160/TH08-02-0096

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 99(04): 647-650
DOI: 10.1160/TH08-02-0096

Editorial Focus

Schattauer GmbH

Angiogenesis and the progress of vascular and tumor biology: A tribute to Judah Folkman

Maria Benedetta Donati

¹Research Laboratories, “John Paul II” Centre for High Technology and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

,

Joanna Gozdzikiewicz^*

¹Research Laboratories, “John Paul II” Centre for High Technology and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

› Author Affiliations

Abstract

Full Text

References

References
1 Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
2 Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966; 164: 491-502.
3 Folkman J, Merler E, Abernathy C. et al. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-288.
4 Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
5 Gimbrone MA, Jr Leapman SB, Cotran RS. et al. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136: 261-276.
6 Brem H, Folkman J. Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 1975; 41: 427-439.
7 Jaffe EA, Nachman RL, Becker CG. et al. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-2756.
8 Gimbrone MA, Jr Cotran RS, Folkman J. Human vascular endothelial cells in culture. Growth and DNA synthesis. J Cell Biol 1974; 60: 673-684.
9 Folkman J, Haudenschild CC, Zetter BR. Longterm culture of capillary endothelial cells. Proc Natl Acad Sci USA 1979; 10: 5217-5221.
10 Shing Y, Folkman J, Sullivan R. et al. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 1984; 223: 1296-1299.
11 Yancopoulos GD, Davis S, Gale NW. et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
12 O’Reilly MS, Holmgren L, Shing Y. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
13 O’Reilly MS, Boehm T, Shing Y. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
14 Folkman J. Antiangiogenesis in cancer therapy–endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594-607.
15 Sun Y, Wang J, Liu Y. et al. Results of phase III trial of EndostarTM (rh-endostatin, YH-16) in advanced non-smallcell lung cancer (NSCLC) patients. ASCO Annual Meeting Proceedings 2005; 23 Abstract 16S.
16 Hurwitz H, Fehrenbach L, Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
17 Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
18 Udagawa T, Fernandez A, Achilles EG. et al. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002; 16: 1361-1370.
19 Naumov GN, Bender E, Zurakowski D. et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006; 98: 316-325.
20 Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001; 86: 23-33.
21 Folkman J. Angiogenesis inhibitors. Cancer Biol Therapy. 2003 01 S127-S133.
22 Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents. Bioessays 1991; 13: 31-36.
23 Browder T, Butterfield CE, Kraling BM. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-1886.
24 Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001; 86: 23-33.
25 Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.
26 Kuenen BC. Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors. Pathophysiol Haemost Thromb 2003; 33 (Suppl. 01) 13-14.
27 Zangari M, Anaissie E, Barlogie B. et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-1615.
28 Caine GJ, Lip GY. Thromboembolism associated with new anti-cancer treatment strategies in combination with conventional chemotherapy: new drugs, old risks?. Thromb Haemost 2003; 90: 567-569.
29 Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237-268.
30 Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 2006; 354: 2621-2622.
31 Ezzell C. Starving tumors of their lifeblood. Sci Am 1998; 279: 33-34.